Matches in Nanopublications for { ?s ?p "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 18 of
18
with 100 items per page.
- NP664592.RAZS1U55uQ4Iv_8ti3Qu9FqgFy6_8lLzsD75Tl9NwaClI130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664592.RAZS1U55uQ4Iv_8ti3Qu9FqgFy6_8lLzsD75Tl9NwaClI130_provenance.
- NP865324.RAXRRRRhg0lyKnFfH5aB7OHcdYOUkSdO0KLvQHEot2GcY130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865324.RAXRRRRhg0lyKnFfH5aB7OHcdYOUkSdO0KLvQHEot2GcY130_provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP865175.RAkz6p0HA2fGnla9ZVQBhwTKOLu42HkCALURvE8E4Xidg130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP865175.RAkz6p0HA2fGnla9ZVQBhwTKOLu42HkCALURvE8E4Xidg130_provenance.
- NP1205969.RAZysEdFMxixcrHpFj7dhweddBcBNuQMLhGJs0gma24FI130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205969.RAZysEdFMxixcrHpFj7dhweddBcBNuQMLhGJs0gma24FI130_provenance.
- NP1205976.RAc-cGycPijOeUNoq_n3zFxQydDh2Cg6-xzA-Z7Ci1Hjk130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205976.RAc-cGycPijOeUNoq_n3zFxQydDh2Cg6-xzA-Z7Ci1Hjk130_provenance.
- NP620756.RAsnhwMXpkMiaD-F3YBqUcbpp3tCmn0AUVNfE5zQxXbHs130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620756.RAsnhwMXpkMiaD-F3YBqUcbpp3tCmn0AUVNfE5zQxXbHs130_provenance.
- NP621759.RArMQ7v3ZmbJgmAFJkvchfDu6OtTiGOIA7cqhXjlKPyTk130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621759.RArMQ7v3ZmbJgmAFJkvchfDu6OtTiGOIA7cqhXjlKPyTk130_provenance.
- NP1205972.RAtjkz-ayuCMjx9slJs9diY9LbqSWi19So_fZT_MPCNO0130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205972.RAtjkz-ayuCMjx9slJs9diY9LbqSWi19So_fZT_MPCNO0130_provenance.
- NP1205973.RAhJ9lFR14KMG7K7AUGM1N2T3H67qf2FkkjyR1fRWpSMM130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205973.RAhJ9lFR14KMG7K7AUGM1N2T3H67qf2FkkjyR1fRWpSMM130_provenance.
- NP1205977.RAqsLR7RIO0_1sfCdRjYsarWWMkCg4GHRu4Ipb9frd-E4130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205977.RAqsLR7RIO0_1sfCdRjYsarWWMkCg4GHRu4Ipb9frd-E4130_provenance.
- NP1205981.RApGtxq9FGt9eSkh5HLUZHVtdrSSUOUlobDf05Mh4dEPo130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1205981.RApGtxq9FGt9eSkh5HLUZHVtdrSSUOUlobDf05Mh4dEPo130_provenance.
- NP664242.RAwuqV3qG6uJcd7b2ok-ueDDRTYagQfUpzXcRZ1cIHMhI130_assertion description "[PIK3CA mutations are present in approximately 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare inluminal BC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP664242.RAwuqV3qG6uJcd7b2ok-ueDDRTYagQfUpzXcRZ1cIHMhI130_provenance.